The FDA announced that it has approved Tris Pharma’s extended-release amphetamine oral suspension (Dyanavel XR) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older. The drug, developed using the manufacturer’s LiquiXR technology, is now the first and only once-daily, extended-release, amphetamine-based oral liquid to be granted FDA approval for treating ADHD